About Jecure Therapeutics
Jecure Therapeutics is a company based in San Diego (United States) founded in 2015 was acquired by Genentech in November 2018. Jecure Therapeutics has raised $18.02 million across 3 funding rounds from investors including Genentech and Versant Ventures. Jecure Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Jecure Therapeutics
Jecure Therapeutics has successfully raised a total of $18.02M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Jecure Therapeutics
Jecure Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
R&D company focused on manufacturing drugs for multiple therapeutic areas
|
Locked | Locked | Locked |
Investor details for Jecure Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jecure Therapeutics
Investment portfolio details for Jecure Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Jecure Therapeutics
Detailed financials for Jecure Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jecure Therapeutics Comparisons
Peer comparison for Jecure Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jecure Therapeutics
Jecure Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for metabolic disorders are developed.
|
Detailed competitors of Jecure Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jecure Therapeutics
Complete news archive for Jecure Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jecure Therapeutics
Jecure Therapeutics was founded in 2015.
Jecure Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Jecure Therapeutics is a funded company, having raised a total of $18.02M across 3 funding rounds to date.
Jecure Therapeutics was founded in 2015 in San Diego, United States, within the biotechnology sector. Focus is placed on the discovery and development of novel therapeutics targeting nonalcoholic steatohepatitis (NASH) and liver fibrosis. Operations center on a lead program featuring a proprietary small molecule inhibitor directed at an undisclosed novel target identified as a pro-inflammatory driver in NASH.
Jecure Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
Jecure Therapeutics has 2 investors. Key investors include Genentech, and Versant Ventures.